ScFvs as Allosteric Inhibitors of VEGFR-2: Novel Tools to Harness VEGF Signaling.

about

Optimized Expression and Characterization of a Novel Fully Human Bispecific Single-Chain Diabody Targeting Vascular Endothelial Growth Factor165 and Programmed Death-1 in and Evaluation of Antitumor Activity In Vivo

P2860

Q59138239-B6EBABB3-4FF3-48EA-A332-8F8EFE1BBA64

P2860

ScFvs as Allosteric Inhibitors of VEGFR-2: Novel Tools to Harness VEGF Signaling.

Item

http://www.wikidata.org/entity/Q54112592

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

ScFvs as Allosteric Inhibitors of VEGFR-2: Novel Tools to Harness VEGF Signaling.

@en

ScFvs as Allosteric Inhibitors of VEGFR-2: Novel Tools to Harness VEGF Signaling.

@nl

type

Item

label

ScFvs as Allosteric Inhibitors of VEGFR-2: Novel Tools to Harness VEGF Signaling.

@en

ScFvs as Allosteric Inhibitors of VEGFR-2: Novel Tools to Harness VEGF Signaling.

@nl

prefLabel

ScFvs as Allosteric Inhibitors of VEGFR-2: Novel Tools to Harness VEGF Signaling.

@en

ScFvs as Allosteric Inhibitors of VEGFR-2: Novel Tools to Harness VEGF Signaling.

@nl

P1476

ScFvs as Allosteric Inhibitors of VEGFR-2: Novel Tools to Harness VEGF Signaling.

@en

P2093

Caroline A C Hyde

http://www.w3.org/2001/XMLSchema#string

Dragana Avramovic

http://www.w3.org/2001/XMLSchema#string

Thomas Schleier

http://www.w3.org/2001/XMLSchema#string

P2860

Targeting extracellular domains D4 and D7 of vascular endothelial growth factor receptor 2 reveals allosteric receptor regulatory sites

Selection and characterization of high affinity VEGFR1 antibodies from a novel human binary code scFv phage library.

Direct contacts between extracellular membrane-proximal domains are required for VEGF receptor activation and cell signaling

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells.

Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy.

By-passing immunization. Human antibodies from V-gene libraries displayed on phage.

P31

scholarly article

P356

10.3390/IJMS19051334

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Kurt Ballmer-Hofer

P577

2018-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29723982

http://www.w3.org/2001/XMLSchema#string

P921

allosteric inhibitor

P932

5983656

http://www.w3.org/2001/XMLSchema#string

ScFvs as Allosteric Inhibitors of VEGFR-2: Novel Tools to Harness VEGF Signaling.

about

P2860

P2860

ScFvs as Allosteric Inhibitors of VEGFR-2: Novel Tools to Harness VEGF Signaling.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932